<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764708</url>
  </required_header>
  <id_info>
    <org_study_id>03-07072020</org_study_id>
    <nct_id>NCT04764708</nct_id>
  </id_info>
  <brief_title>Compassion and Metacognition in Schizotypal Personality</brief_title>
  <acronym>CMBT</acronym>
  <official_title>Compassion and Metacognition Based Therapy for Schizotypal Personality Disorder: A Pilot Non-inferiority Randomized Controlled Trial on Repeated Measures.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tages Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tages Onlus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of a newly developed&#xD;
      psychotherapy for schizotypal personality disorder. This new form of psychotherapy integrates&#xD;
      compassion focused therapy and metacognitively oriented psychotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written&#xD;
      informed consent will undergo a psychological assessment so as to determine eligibility for&#xD;
      study entry. Patients who meet the eligibility requirements will be randomized in a&#xD;
      double-blind manner in a 1:1 ratio to new integrative psychotherapy or treatment as usual&#xD;
      (cognitive behavioral therapy plus standard psychopharmacological treatment). One month after&#xD;
      the conclusion of the two forms of treatment (both lasting 6 months), patients will have&#xD;
      access to the final follow-up assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial with Repeated Measures</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Personality Pathology at 8 months</measure>
    <time_frame>9 measurements over the course of 8 months: (i) at 1 month before intervention starts; (ii) once the treatment starts; (iii) 6 measurements at the end of each month of intervention; iv) at 1-month follow-up.</time_frame>
    <description>Decrese of Personality Inventory for DSM-5 - Brief Form (PID-5-BF) total score (with a range of 0 to 75; higher scores indicating a more severe psychopathology) from baseline to final assessment after 8 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Schizotypal Personality Disorder Diagnosis (SPD)</measure>
    <time_frame>Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment.</time_frame>
    <description>Recovery from SPD diagnosis at Module III of Structural Clinical Interview for DSM-5 Alternative Model of Personality Disorders (SCID-5-AMPD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Psychopathology</measure>
    <time_frame>Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment.</time_frame>
    <description>Decrease of Global Severity Index (with a range of 0 to 4; higher scores indicating a more severe psychopathology) of the Symptom Checklist-90-R (SCL-90-R).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metacognition</measure>
    <time_frame>Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment.</time_frame>
    <description>Increase of Metacognition Assessment Scale - Abreviated (MAS-A) total score (with a range of 0 to 28; higher scores indicating higher metacognitive functioning).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Schizotypal Personality Disorder</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cognitive behavioral therapy plus standard psychopharmacological treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Third Wave Cognitive Therapy that integrates Compassion Focused Therapy and Metacognitively Oriented Psychotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Compassion and Metacognition Based Therapy</intervention_name>
    <description>The intervention is a Third Wave Cognitive Therapy targeting metacognitive dysfuctions (through Metacognitively Oriented Psychotherapy) and self-criticism (through Compassion Focused Therapy).</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>Standard Cognitive Behavioral Therapy for Personality Disorders plus Standard Psychopharmacological Treatment.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Standard Psychopharmacological Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Being diagnosed with Schizotypal Personality Disorder at SCID-5-AMPD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Being under psychotherapy or psychopahrnacological treatment&#xD;
&#xD;
          -  Being diagnosed with schizophrenia and other psychotic disorders&#xD;
&#xD;
          -  Being diagnosed with bipolar disorder&#xD;
&#xD;
          -  Being diagnosed with intelletual disability&#xD;
&#xD;
          -  Being diagnosed with any neurological disases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simone Cheli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tages Onlus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gil Goldzweig</last_name>
    <role>Study Chair</role>
    <affiliation>The Academic College of Tel-Aviv Yaffo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Cheli</last_name>
    <phone>+393285642442</phone>
    <email>simone.cheli@tagesonlus.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marta Floridi</last_name>
    <email>marta.floridi@tagesonlus.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro di Psicologia e Psicoterapia Tages Onlus - Firenze</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50137</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Cavalletti</last_name>
      <phone>+39 055 679037</phone>
      <email>veronica.cavalletti@tagesonlus.org</email>
    </contact>
    <contact_backup>
      <last_name>Marta Floridi</last_name>
      <email>marta.floridi@tagesonlus.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centro di Psicologia e Psicoterapia Tages Onlus - Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40068</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Cheli S, Lysaker PH, Dimaggio G. Metacognitively oriented psychotherapy for schizotypal personality disorder: A two-case series. Personal Ment Health. 2019 Aug;13(3):155-167. doi: 10.1002/pmh.1447. Epub 2019 Jun 6.</citation>
    <PMID>31169366</PMID>
  </reference>
  <reference>
    <citation>Cheli S. Assessment and treatment planning for schizotypal personality disorder: A metacognitively oriented point of view. Psychiatr Rehabil J. 2020 Dec;43(4):335-343. doi: 10.1037/prj0000429. Epub 2020 May 28.</citation>
    <PMID>32463252</PMID>
  </reference>
  <reference>
    <citation>Petrocchi N, Cheli S. The social brain and heart rate variability: Implications for psychotherapy. Psychol Psychother. 2019 Jun;92(2):208-223. doi: 10.1111/papt.12224. Epub 2019 Mar 20. Review.</citation>
    <PMID>30891894</PMID>
  </reference>
  <reference>
    <citation>Lysaker PH, Dimaggio G, Hamm JA, Leonhardt BL, Hochheiser J, Lysaker JT. Disturbances in Self-Experience in Schizophrenia: Metacognition and the Development of an Integrative Recovery-Oriented Individual Psychotherapy. Psychopathology. 2019;52(2):135-142. doi: 10.1159/000495297. Epub 2018 Dec 11.</citation>
    <PMID>30537720</PMID>
  </reference>
  <reference>
    <citation>Dimaggio G, Lysaker PH. Metacognition and mentalizing in the psychotherapy of patients with psychosis and personality disorders. J Clin Psychol. 2015 Feb;71(2):117-24. doi: 10.1002/jclp.22147. Epub 2014 Dec 31.</citation>
    <PMID>25557317</PMID>
  </reference>
  <reference>
    <citation>Lysaker PH, Gagen E, Klion R, Zalzala A, Vohs J, Faith LA, Leonhardt B, Hamm J, Hasson-Ohayon I. Metacognitive Reflection and Insight Therapy: A Recovery-Oriented Treatment Approach for Psychosis. Psychol Res Behav Manag. 2020 Apr 2;13:331-341. doi: 10.2147/PRBM.S198628. eCollection 2020. Review.</citation>
    <PMID>32308511</PMID>
  </reference>
  <reference>
    <citation>Lysaker PH, Hamm JA, Hasson-Ohayon I, Pattison ML, Leonhardt BL. Promoting recovery from severe mental illness: Implications from research on metacognition and metacognitive reflection and insight therapy. World J Psychiatry. 2018 Mar 22;8(1):1-11. doi: 10.5498/wjp.v8.i1.1. eCollection 2018 Mar 22. Review.</citation>
    <PMID>29568726</PMID>
  </reference>
  <reference>
    <citation>Dimaggio G, Semerari A, Carcione A, Procacci M, Nicolò G. Toward a model of self pathology underlying personality disorders: narratives, metacognition, interpersonal cycles and decision-making processes. J Pers Disord. 2006 Dec;20(6):597-617. Review.</citation>
    <PMID>17192140</PMID>
  </reference>
  <reference>
    <citation>Kramer U, Beuchat H, Grandjean L, Pascual-Leone A. How Personality Disorders Change in Psychotherapy: a Concise Review of Process. Curr Psychiatry Rep. 2020 Jun 9;22(8):41. doi: 10.1007/s11920-020-01162-3. Review.</citation>
    <PMID>32519017</PMID>
  </reference>
  <reference>
    <citation>Heriot-Maitland C, McCarthy-Jones S, Longden E, Gilbert P. Compassion Focused Approaches to Working With Distressing Voices. Front Psychol. 2019 Feb 1;10:152. doi: 10.3389/fpsyg.2019.00152. eCollection 2019.</citation>
    <PMID>30774614</PMID>
  </reference>
  <reference>
    <citation>Kirby JN, Tellegen CL, Steindl SR. A Meta-Analysis of Compassion-Based Interventions: Current State of Knowledge and Future Directions. Behav Ther. 2017 Nov;48(6):778-792. doi: 10.1016/j.beth.2017.06.003. Epub 2017 Jun 21. Review.</citation>
    <PMID>29029675</PMID>
  </reference>
  <reference>
    <citation>Leaviss J, Uttley L. Psychotherapeutic benefits of compassion-focused therapy: an early systematic review. Psychol Med. 2015 Apr;45(5):927-45. doi: 10.1017/S0033291714002141. Epub 2014 Sep 12. Review.</citation>
    <PMID>25215860</PMID>
  </reference>
  <reference>
    <citation>Lucre K, Clapton N. The Compassionate Kitbag: A creative and integrative approach to compassion-focused therapy. Psychol Psychother. 2021 Apr;94 Suppl 2:497-516. doi: 10.1111/papt.12291. Epub 2020 Jul 8. Review.</citation>
    <PMID>32639097</PMID>
  </reference>
  <reference>
    <citation>Braehler C, Gumley A, Harper J, Wallace S, Norrie J, Gilbert P. Exploring change processes in compassion focused therapy in psychosis: results of a feasibility randomized controlled trial. Br J Clin Psychol. 2013 Jun;52(2):199-214. doi: 10.1111/bjc.12009. Epub 2012 Oct 24.</citation>
    <PMID>24215148</PMID>
  </reference>
  <reference>
    <citation>Cohen AS, Mohr C, Ettinger U, Chan RC, Park S. Schizotypy as an organizing framework for social and affective sciences. Schizophr Bull. 2015 Mar;41 Suppl 2:S427-35. doi: 10.1093/schbul/sbu195. Review.</citation>
    <PMID>25810057</PMID>
  </reference>
  <reference>
    <citation>Debbané M, Eliez S, Badoud D, Conus P, Flückiger R, Schultze-Lutter F. Developing psychosis and its risk states through the lens of schizotypy. Schizophr Bull. 2015 Mar;41 Suppl 2:S396-407. doi: 10.1093/schbul/sbu176. Epub 2014 Dec 29. Review.</citation>
    <PMID>25548386</PMID>
  </reference>
  <reference>
    <citation>Mason OJ. The assessment of schizotypy and its clinical relevance. Schizophr Bull. 2015 Mar;41 Suppl 2:S374-85. doi: 10.1093/schbul/sbu194. Review.</citation>
    <PMID>25810054</PMID>
  </reference>
  <reference>
    <citation>Bora E. Theory of mind and schizotypy: A meta-analysis. Schizophr Res. 2020 Aug;222:97-103. doi: 10.1016/j.schres.2020.04.024. Epub 2020 May 25. Review.</citation>
    <PMID>32461089</PMID>
  </reference>
  <reference>
    <citation>Grant P, Green MJ, Mason OJ. Models of Schizotypy: The Importance of Conceptual Clarity. Schizophr Bull. 2018 Oct 15;44(suppl_2):S556-S563. doi: 10.1093/schbul/sby012. Review.</citation>
    <PMID>29474661</PMID>
  </reference>
  <reference>
    <citation>Kirchner SK, Roeh A, Nolden J, Hasan A. Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review. NPJ Schizophr. 2018 Oct 3;4(1):20. doi: 10.1038/s41537-018-0062-8. Review.</citation>
    <PMID>30282970</PMID>
  </reference>
  <reference>
    <citation>Rosell DR, Futterman SE, McMaster A, Siever LJ. Schizotypal personality disorder: a current review. Curr Psychiatry Rep. 2014 Jul;16(7):452. doi: 10.1007/s11920-014-0452-1. Review.</citation>
    <PMID>24828284</PMID>
  </reference>
  <reference>
    <citation>Balaratnasingam S, Janca A. Normal personality, personality disorder and psychosis: current views and future perspectives. Curr Opin Psychiatry. 2015 Jan;28(1):30-4. doi: 10.1097/YCO.0000000000000124. Review.</citation>
    <PMID>25415496</PMID>
  </reference>
  <reference>
    <citation>Volkert J, Gablonski TC, Rabung S. Prevalence of personality disorders in the general adult population in Western countries: systematic review and meta-analysis. Br J Psychiatry. 2018 Dec;213(6):709-715. doi: 10.1192/bjp.2018.202. Epub 2018 Sep 28.</citation>
    <PMID>30261937</PMID>
  </reference>
  <reference>
    <citation>Wilson S, Stroud CB, Durbin CE. Interpersonal dysfunction in personality disorders: A meta-analytic review. Psychol Bull. 2017 Jul;143(7):677-734. doi: 10.1037/bul0000101. Epub 2017 Apr 27. Review.</citation>
    <PMID>28447827</PMID>
  </reference>
  <reference>
    <citation>Cheli S, Cavalletti V, Petrocchi N (2020) An online compassion-focused crisis intervention during COVID-19 lockdown: a cases series on patients at high risk for psychosis, Psychosis, 12:4, 359-362, DOI: 10.1080/17522439.2020.1786148</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tages Onlus</investigator_affiliation>
    <investigator_full_name>Simone Cheli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>schizotypy</keyword>
  <keyword>psychotherapy</keyword>
  <keyword>compassion-focused therapy</keyword>
  <keyword>metacognitively oriented psychotherapy</keyword>
  <keyword>metacognition</keyword>
  <keyword>compassion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Schizotypal Personality Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual partecipants data underline the results in all the future publications related to the trial will be available after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be released at the end of the study and will be accessible permanently.</ipd_time_frame>
    <ipd_access_criteria>IPD will be accessible on a dedicated web adress inside Tages Onlus website. The page will be released after the end of the study.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 17, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT04764708/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

